Savara announces offering of common stock and warrants, no amount given

Savara (SVRA) announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. Savara intends to use the proceeds of the offering for general corporate purposes, which include the funding of clinical development of and pursuing regulatory approval for MOLBREEVI*, investing in commercialization infrastructure and supply, commercial launch preparation activities in the United States and European Union, and general and administrative expenses. In addition, Savara intends to grant the underwriters of the proposed offering a 30-day option to purchase up to an additional 15% of the number of shares of common stock and pre-funded warrants offered. Jefferies, Piper Sandler, and Guggenheim Securities are acting as joint book-running managers for the proposed offering. Oppenheimer & Co. is acting as the lead manager, and Citizens Capital Markets and H.C. Wainwright & Co. are acting as co-managers for the proposed offering.